- Home
- O vs REGN Comparison
O vs REGN Comparison
Compare O & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- O
- REGN
- Stock Information
- Founded
- O 1969
- REGN 1988
- Country
- O United States
- REGN United States
- Employees
- O N/A
- REGN N/A
- Industry
- O Real Estate Investment Trusts
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- O Real Estate
- REGN Health Care
- Exchange
- O Nasdaq
- REGN Nasdaq
- Market Cap
- O 55.1B
- REGN 59.5B
- IPO Year
- O N/A
- REGN 1991
- Fundamental
- Price
- O $58.74
- REGN $560.51
- Analyst Decision
- O Hold
- REGN Buy
- Analyst Count
- O 13
- REGN 23
- Target Price
- O $61.67
- REGN $795.04
- AVG Volume (30 Days)
- O 5.5M
- REGN 1.2M
- Earning Date
- O 11-03-2025
- REGN 10-28-2025
- Dividend Yield
- O 5.50%
- REGN 0.63%
- EPS Growth
- O N/A
- REGN 5.03
- EPS
- O 1.03
- REGN 39.67
- Revenue
- O $5,477,163,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- O $6.33
- REGN N/A
- Revenue Next Year
- O $4.67
- REGN $4.74
- P/E Ratio
- O $57.25
- REGN $14.06
- Revenue Growth
- O 16.10
- REGN 5.38
- 52 Week Low
- O $50.71
- REGN $476.49
- 52 Week High
- O $64.88
- REGN $1,024.36
- Technical
- Relative Strength Index (RSI)
- O 43.74
- REGN 43.91
- Support Level
- O $59.82
- REGN $555.00
- Resistance Level
- O $60.74
- REGN $577.17
- Average True Range (ATR)
- O 0.64
- REGN 19.98
- MACD
- O -0.26
- REGN -2.52
- Stochastic Oscillator
- O 25.27
- REGN 25.33
About O Realty Income Corporation
Realty Income owns roughly 15,600 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, gaming, office, manufacturing, and distribution properties, which make up roughly 20% of revenue.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).